The Multiple Myeloma Market would experience the CAGR of 4.5% from 2021 to 2028.

The Multiple Myeloma Market would experience the CAGR of 4.5% from 2021 to 2028. A rare type of cancer occurred inside the white blood cell or plasma cell. Plasma cells become uncontrollable and stretch out of control then it becomes cancerous, this is termed as multiple myeloma. Such plasma cells produce abnormal protein or antibody (monoclonal immunoglobulin, monoclonal protein, M-spike). Globally, multiple myeloma is the second highest occurrence blood cancer accounting to about 160,000 annually. Report by National Cancer Institute in U.S cases of multiple myeloma accounts for 30,770 per year and about 1.7% of all new cases of cancer is myeloma.

Substantial improvement of healthcare amenities and increasing prevalence of cancer globally augments for the rise of the global multiple market. Advanced therapeutics and extensive R&D activity efficient in boosting the multiple myeloma market. Immunomodulators acts as an emerging therapy for the treatment of numerous cancers cases resulting positive treatment outcomes. Proteasome inhibitor treatment method accounts for significant share owing to plenty of product offerings. By distribution channel, hospitals segment dominates highest share in the market.

By drug type, multiple myeloma comprises numerous drugs such as immunomodulatory drugs, proteasome inhibitors, monoclonal antibody drugs and many more. Such drugs aids in preventing bone fracture, spinal cord compression, anaemia and promotes bone healing.

Geographically, North America holds the highest share owing to regulated framework, demand for the disease treatment, adaption of newer advanced technologies and healthcare infrastructure and patient awareness for the treatment benefit of the multiple myeloma. European region accounts second for the market share owing to numerous prominent players in the region and population growth. Asia- Pacific imparts lucrative opportunities for the multiple myeloma market growth owing to increased disposable income and generic manufacturers in the region.

Multiple Myeloma Diagnosis demands

  • Plasma cell tumor
  • Any one of the mentioned below
    • High blood calcium cells
    • Poor kidney functionality
    • Low Red Blood Cells
    • Holes in bones from tumor
    • Above 60 % plasma cells in the bone marrow

Prominent competitors inducing the Multiple Myeloma Market are Takeda Pharmaceutical Company Limited, Celegene Corporation, Kyprolis, Bristol Myers Squibb Company, AbbVie Inc., and Sanofi, among others. 

Multiple Myeloma Market Segmentation:

  • Breakup by Therapy
    • Targeted Therapy
    • Biologic Therapy
    • Chemotherapy
    • Others
    • Breakup by Drug Type
      • Immunomodulatory Drugs
      • Proteasome Inhibitors
      • Histone Deacetylase Inhibitors
      • Monoclonal Antibody Drugs
      • Steroids
      • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies & Drug Stores
        • Online Pharmacies

By Region

  • North America
    • US
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of the World (RoW)
    • South & Central America
    • Middle East
    • Africa